The Value of Protocol Biopsies to Identify Patients With De Novo Donor-Specific Antibody at High Risk for Allograft Loss
Carrie A. Schinstock(Mayo Clinic), Mark D. Stegall(Mayo Clinic in Arizona), Borja G. Cosío(Hospital Universitario Son Espases), Matthew J. Everly(Terasaki Foundation), Darshana M. Dadhania(NewYork–Presbyterian Hospital), Wisit Cheungpasitporn(Mayo Clinic), Lynn D. Cornell(University of Calgary), Milagros Samaniego(Henry Ford Health System)
Cited by 103
Related Papers
Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions
|American Journal of Transplantation|2008|1.9k
Banff 2013 Meeting Report: Inclusion of C4d-Negative Antibody-Mediated Rejection and Antibody-Associated Arterial Lesions
|American Journal of Transplantation|2014|1.3k
KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 Update
|American Journal of Kidney Diseases|2015|1.3k
The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials
|American Journal of Transplantation|2017|1k
COVID-19 in solid organ transplant recipients: Initial report from the US epicenter
|American Journal of Transplantation|2020|837